BioAegis Therapeutics
Morristown, US · Founded 2011 · Delaware corporation
BioAegis Therapeutics is a clinical-stage biotech developing therapies for infectious and non-infectious inflammatory diseases based on a recombinant human form of plasma gelsolin (rhu-pGSN), a blood protein that regulates the immune response. Its platform aims to restore depleted gelsolin levels to control inflammation without suppressing immune function.
Founders & leadership
BioAegis Therapeutics was founded in 2011 by Susan Levinson.
SL
Susan LevinsoninFounder · Chief Executive OfficerSusan Levinson holds a Ph.D. in Biomedical Sciences with a focus on Biochemistry and brings experience in business development, strategic consulting, and operations within life sciences. She serves as Executive Officer and Director at BioAegis Therapeutics, a clinical-stage biotech developing immunomodulatory therapies.
VC
Valerie CevainCOO
SC
Steve CordovanoinCo-Founder
TS
Thomas StosselNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$42.4M disclosed across 5 rounds · 2012–2021
▶$21.8MraisedMay 2022 · 27 investors · BiotechnologyRule 506(b)
▶$21.8MraisedMay 2022 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Valerie CevaExecutive Officer, Director
- Mark DiNubileExecutive Officer, Director
- Susan LevinsonExecutive Officer, Director
- Offering amount
- $21.8M
- Amount sold
- $21.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedOct 2020 · 147 investors · BiotechnologyRule 506(b)
▶$7MraisedOct 2020 · 147 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Susan LevinsonExecutive Officer, Director
- John StosselDirector
- Mark DiNubileExecutive Officer, Director
- Valerie CevaExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedSep 2018 · 10 investors · BiotechnologyRule 506(b)
▶$4.1MraisedSep 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark DiNubileExecutive Officer
- Thomas StosselExecutive Officer, Director
- Valerie CevaExecutive Officer, Director
- Susan LevinsonExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $4.1M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2016 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMar 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven CordovanoExecutive Officer
- Thomas StosselExecutive Officer, Director
- Susan LevinsonExecutive Officer, Director
- Valerie CevaExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.5M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedApr 2015 · 77 investors · BiotechnologyRule 506(b)
▶$8MraisedApr 2015 · 77 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Valerie CevaExecutive Officer, Director
- Thomas StosselDirector
- Susan LevinsonExecutive Officer, Director
- Steve CordovanoExecutive Officer
- Amount sold
- $8M
- First sale
- Mar 2012
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Epi Biologics4 shared keywordsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Doximity4 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
EquityZen4 shared keywordsEquityZen operates an online marketplace that gives accredited individual investors access to shares in late-stage private companies through secondary market transactions. Now part of Morgan Stanley, the platform provides private market data, offering documents, and guided investment processes for buying and selling pre-IPO equity.
Companies competing with BioAegis Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does BioAegis Therapeutics do?
- BioAegis Therapeutics is a clinical-stage biotech developing therapies for infectious and non-infectious inflammatory diseases based on a recombinant human form of plasma gelsolin (rhu-pGSN), a blood protein that regulates the immune response. Its platform aims to restore depleted gelsolin levels to control inflammation without suppressing immune function.
- Who founded BioAegis Therapeutics?
- BioAegis Therapeutics was founded by Susan Levinson in 2011.
- How much funding has BioAegis Therapeutics raised?
- BioAegis Therapeutics has disclosed $42.4M raised across 5 rounds.
- Where is BioAegis Therapeutics headquartered?
- BioAegis Therapeutics is headquartered in Morristown, US.